Published in
American Society of Hematology, Blood Advances, 23(4), p. 6034-6038, 2020
DOI: 10.1182/bloodadvances.2020003326
Links
Tools
A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Journal article published in 2020 by
Wenbin Xiao 
,
Linde A. Miles,
Robert L. Bowman,
Vidushi Durani,
Helen S. Tian,
Nicole L. DelGaudio,
Tanmay Mishra,
Menglei Zhu,
Yanming Zhang,
Sarah E. Stump ,
Martin S. Tallman,
Ross L. Levine ,
Sheng F. Cai
,
Linde A. Miles,
Robert L. Bowman,
Vidushi Durani,
Helen S. Tian,
Nicole L. DelGaudio,
Tanmay Mishra,
Menglei Zhu,
Yanming Zhang,
Sarah E. Stump ,
Martin S. Tallman,
Ross L. Levine ,
Sheng F. Cai
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.